Hemostasis in normal pregnancy

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 6-10

  Brenner, B ^a   Aharon, A ^a   Lanir, N ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRIN; FIBRINOGEN; INTERLEUKIN 1; PLASMINOGEN ACTIVATOR INHIBITOR; PROCOAGULANT; THROMBOMODULIN; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR;

APOPTOSIS; BLOOD FLOW; CELL ACTIVATION; CONFERENCE PAPER; CORRELATION ANALYSIS; DECIDUALIZATION; DISEASE MARKER; FIBRINOLYSIS; FIRST TRIMESTER PREGNANCY; GENE MUTATION; HEMOSTASIS; HUMAN; MATERNAL BLOOD; MEMBRANE VESICLE; NONHUMAN; PATHOPHYSIOLOGY; PLACENTA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SYNCYTIOTROPHOBLAST; T LYMPHOCYTE; THIRD TRIMESTER PREGNANCY; THROMBOCYTE; THROMBOSIS; TROPHOBLAST;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; FEMALE; HEMOSTASIS; HUMANS; PLACENTAL CIRCULATION; PREGNANCY;

EID: 12544256876     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984;52:176-82.
2. Greer IA, Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors Haemostasis and thrombosis in pregnancy. Haemostasis and thrombosis 3rd edn ed. Churchill Livingstone, Edinburgh; 1994. p. 987-1015.
3. Beller FK, Ebert C. The coagulation and fibrinolytic enzyme systems in normal pregnancy and the puerperium. Eur J Obstet Gynecol Reprod Biol 1982;13:177-97.
4. Boffa MC, Valsecchi L, Fausto A. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost 1998;79:1092-5.
5. Gonzalez R, Alberca I, Vicente V. Protein C levels in late pregnancy, postpartum and in women on oral contraceptives. Thromb Res 1985;39:637-40.
6. Gilabert J, Fernandez JA, Espana F, Aznar J, and Estelles A. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988;49:319-29.
7. Bremme K, Ostlund E, Almqvist I. Enhanced thrombin generation and fibrinolytic activity in the normal pregnancy and the puerperium. Obstet Gynecol 1992;80:132-7.
8. Kjellberg U, Andersson NE, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999;81:527-31.
9. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, and Walker ID. Activated protein C sensitivity. Protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998;79:1166-70.
10. Dahlbäck B, Carlsson M, PSvensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by a poor anticoagulant response to activated protein C. Proceedings of the National Academy of Sciences of the USA 1993;94:1004-8.
11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
12. Bokarewa MI, Bremme K, Falk G, Sten-Linder M, Egberg N, Blomback M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995;78:193-200.
13. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001;110:91-6.
14. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, and Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995;90:725-7.
15. Mathonnet F, de Mazancourt P, Bastenaire B, Morot M, Benattar N, Beufe S, Borg JY, Giudicelli Y. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol 1996;92:244-6.
16. Bokarewa MI, Wramsby M, Bremme K, Blomback M. Variability of the response to activated protein C during normal pregnancy. Blood Coagul Fibrinolysis 1997;8:239-44.
17. Clark P, Sattar N, Walker ID, Greer IA. The Glasgow outcome, APCR and Lipid (GOAL) pregnancy study: significance of pregnancy associated activated protein. Thromb Haemost 2001;85:30-5.
18. Walker MC, Garner PR, Keely EJ, Rock GA, Reis MD. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997;177:162-9.
19. Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004;103:4173-9.
20. Eichinger S, Weltermann A, Philipp K, Hafner E, Kaider A, Kittl EM, Brenner B, Mannhalter C, Lechner K, Kyrle PA. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999;82:1232-6.
21. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999;81:532-7.
22. Vasse M, Leduc O, Borg JY, Chretien MH, Monconduit M. Resistance to activated protein C-evaluation of three functional assays. Thromb Res 1994;76:47-59.
23. Ishii A, Yamada R, Hamada H. t-PA activity in peripheral blood obtained from pregnant women. J Perinat Med 1994;22:113-7.
24. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator and inhibitors. Blood 1987;69:460-6.
25. Craven CM, Chedwick LR, Ward K. Placental basal plate formation is associated with fibrin deposition in decidual veins at sites of trophoblast cell invasion. Am J Obstet Gynecol 2002;186:291-6.
26. Sheppard BL, Bonnar J. Uteroplacental haemostasis in intrauterine fetal growth retardation. Semin Thromb Hemost 1999;25:443-6.
27. Lockwood CJ, Krikun G, Runic R, Schwartz LB, Mesia AF, Schatz F. Progestin epidermal growth factor regulation of tissue factor expression during decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 2000;85:297-301.
28. Lanir N, Aharon A, Brenner B. Haemostatic mechanisms in human placenta. Best Pract Res Clin Haematol 2003;16:183-95.
29. Aharon A, Brenner B, Miyagi Y, Katz T, Lanir N. Tissue factor and tissue factor pathway inhibitor in human cultured trophoblasts. Thromb Haemost 2004;92:776-86.
30. Van Wijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular disease. Cardiovasc Res 2003;59:277-8.
31. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104:93-102.
32. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101:841-3.
33. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selection glycoprotein ligand 1 and platelet P-selection. J Exp Med 2003;197:1585-98.
34. Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V, D'Ercole C, Dignat-George F. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003;89:486-92.
35. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, Wold M. Mairovitz V, Hugel B, Freyssinet JM, Frydman R, Meyer D, Eschwege V. Circulation procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001;85:18-21.
36. Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endotheliumdependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 2002;187:1686-93.
37. Harlow FH, Brown MA, Brighton TA, Smith SL, Trickett AE, Kwan YL, Davis GK. Platelet activation in the hypertensive disorders of pregnancy. Am J Obsted Gynecol 2002;187:688-95.
38. Van Wijk MJ, Boer K, Berckmans RJ, Meijers JC, van der Post JA, Sturk A, Van Bavel E, Nieuwland R. Enhanced coagulation activation in preeclampsia: the role of APC resistance micropatricles and other plasma constituents. Thromb Haemost 2002;88:415-20.
39. van Wijk MJ, Nieuwland R, Boer K, van der Post JA, Van Bavel E, Sturk A. Micorpaticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 2002;187:450-6.
40. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in preeclampsia pregnancies. Br J Obstet Gynaecol 1998;105:632-40.